LACTOLOGY FOUNDATION

Sodium tartrate (ATC A06AD21) is an osmotic laxative with minimal systemic absorption, and, by extension, drugs in this class are considered compatible with breastfeeding when used in usual short-term doses in healthy, term infants.medpedia.framar+5

Pharmacological class and mechanism

Sodium tartrate (A06AD21) belongs to the group of osmotic laxatives used for the relief of constipation and difficult defecation.seslhd.nsw+1
As an osmotic agent, it increases intraluminal osmotic pressure in the intestinal lumen, leading to water retention, softening and enlargement of faecal mass, and facilitation of defecation.ncbi.nlm.nih+2

Osmotic laxatives are generally poorly absorbed from the gastrointestinal tract, so systemic exposure after oral administration is low.midlandsmedicines+2
Because systemic exposure is limited, transfer into breast milk is expected to be negligible, which underpins their favourable safety profile in lactation.sps+4

Indications and clinical use

Medicinal products containing sodium tartrate are indicated for short-term treatment of constipation and conditions associated with difficult defecation, where increased stool water content and volume are desired.medpedia.framar+1
They may be used as part of bowel preparation regimens or for intermittent relief of functional constipation when non-pharmacological measures (dietary fibre, fluids, physical activity) are insufficient.breastfeedingnetwork+2

In breastfeeding women, clinical guidance favours osmotic or bulk-forming laxatives as first-line pharmacological options, as they provide effective relief with minimal infant exposure compared with stimulant laxatives.sps+3

Pharmacokinetics and transfer into breast milk

Sodium tartrate, like other small osmotic solutes, acts primarily within the gut lumen; oral bioavailability is limited due to poor intestinal absorption and extensive retention in the gastrointestinal tract.fao+3
Low systemic bioavailability results in very low maternal plasma concentrations, restricting passage into breast milk to levels considered clinically insignificant.medsafe+4

General lactation pharmacology principles state that medicines excreted into breast milk at less than 10% of the maternal dose are usually compatible with breastfeeding, and most laxatives fall within this category.accp+2
Available lactation guidance documents therefore group osmotic laxatives as agents with negligible milk transfer and no expected adverse effects in breastfed infants when standard doses and treatment durations are observed.breastfeedingnetwork+4

Lactation safety and potential infant effects

Specialist breastfeeding resources emphasise that osmotic laxatives can generally be used during breastfeeding, as most are either not absorbed or only minimally absorbed, leading to low or negligible levels in breast milk.ncbi.nlm.nih+3
Consequently, sodium tartrate-containing medicines are considered compatible with breastfeeding in healthy, term infants, and routine interruption of breastfeeding is not required.medsafe+3

Although clinically significant infant effects are unlikely, theoretical risks include mild gastrointestinal symptoms such as soft stools or diarrhoea, reflecting the class effect of laxatives on bowel function.accp+2
As with all medicines during lactation, it is prudent to use the lowest effective dose for the shortest duration and to monitor the infant for changes in stool frequency, consistency, or irritability.utoronto.scholaris+2

Maternal safety considerations

In the mother, sodium tartrate shares the safety profile of osmotic laxatives, with primary adverse effects related to gastrointestinal discomfort, including abdominal distension, cramping, and diarrhoea at higher doses.seslhd.nsw+2
Excessive or prolonged use may lead to electrolyte imbalance and dehydration, particularly in vulnerable patients, so repeated or high-dose administration should be avoided without medical supervision.ncbi.nlm.nih+2

Non-pharmacological measures (dietary fibre optimisation, increased fluid intake, and physical activity) should be optimised before initiating pharmacotherapy for constipation in breastfeeding women, both to minimise medication burden and preserve gut function.breastfeedingnetwork+2
Stimulant laxatives are generally reserved for occasional, short-term use when osmotic or bulk agents are insufficient, due to a higher risk of maternal cramping and potential for more pronounced alterations in bowel habits.seslhd.nsw+2

Use in special populations and clinical precautions

In breastfeeding women with comorbidities such as renal impairment, heart failure, or significant electrolyte disturbances, any osmotic laxative, including sodium tartrate, should be used cautiously because of the potential to exacerbate fluid and electrolyte imbalance.medsafe+2
In premature infants, neonates with gastrointestinal disease, or breastfed infants with diarrhoea, prescribers should individually weigh the maternal benefit of treatment against the theoretical risk of further altering infant stool patterns.utoronto.scholaris+2

When ongoing laxative therapy is anticipated, clinical review is advisable to exclude secondary causes of constipation (e.g. endocrine disease, neurological disorders, medication-induced constipation) and to reassess the need for pharmacological intervention in the context of breastfeeding.accp+2
Across lactation pharmacology guidance, the general recommendation is to maintain breastfeeding while treating maternal constipation, adjusting dosing schedules and formulation choice to minimise infant exposure when feasible.sps+3

Contraindications and drug interactions

Sodium tartrate is contraindicated in individuals with known hypersensitivity to the active substance or to any excipients in the medicinal product.fao+1
It should not be used in cases of intestinal obstruction, severe inflammatory bowel disease, or acute surgical abdomen, where stimulation of bowel movements could aggravate the underlying condition or delay diagnosis.ncbi.nlm.nih+2

Clinically relevant drug–drug interactions for osmotic laxatives are limited, but rapid transit and increased bowel content may reduce absorption of concomitant orally administered medicines, particularly those with a narrow therapeutic index.seslhd.nsw+2
To minimise such interactions, administration of sodium tartrate should ideally be separated in time from critical oral therapies, according to individual pharmacokinetic profiles.utoronto.scholaris+2

Practical recommendations in breastfeeding

Current expert guidance indicates that any laxative, including osmotic agents such as sodium tartrate, can be used during breastfeeding, though prucalopride requires particular caution.midlandsmedicines+2
For breastfeeding women requiring pharmacological treatment of constipation, osmotic laxatives are preferred over routine use of stimulant agents, owing to their minimal systemic absorption and negligible passage into breast milk.midlandsmedicines+3

When possible, dosing can be scheduled immediately after a feed to further reduce infant exposure by exploiting the decline in maternal plasma concentrations before the next breastfeeding episode.medsafe+2
Health professionals should provide clear counselling that short-term use of sodium tartrate is unlikely to harm the breastfed infant, and that maintaining effective maternal bowel function supports continuation of breastfeeding.sps+4